Free public records show Chartwell in 14 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
23 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Chartwell: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Chartwell is in.
Stories on the topics Chartwell works in.
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read